BIT Capital’s Edgewise Therapeutics EWTX Stock Holding History

BIT Capital’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,715	Closed	-$136K	–	113
2023 Q3	$136K	Buy	23,715 +5,052	+27%	+$34.3K	0.02%	91
2023 Q2	$145K	Buy	+18,663	New	+$157K	0.01%	119

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT Capital's EWTX Position: Q4 2023 in Review

BIT Capital sold out of Edgewise Therapeutics (EWTX) in Q4 2023, closing a stake of 23,715 shares — an estimated $136K sold.

BIT Capital first reported a position in EWTX in Q2 2023 and held it in 2 quarters. The position peaked at $145K in Q2 2023. 116 funds tracked by Wall St. Rank hold EWTX as of Q4 2023.

BIT Capital reported no remaining Edgewise Therapeutics position as of Q4 2023 after selling out during the quarter.
BIT Capital sold 23,715 Edgewise Therapeutics shares in Q4 2023, an estimated $136K.
BIT Capital first reported a position in Edgewise Therapeutics in Q2 2023 and held it in 2 quarters.
BIT Capital's Edgewise Therapeutics position peaked at $145K in Q2 2023.
116 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2023.

Based on BIT Capital's 13F filing for Q4 2023, filed 12 Feb 2025.